DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



An Open Long Term Follow up Study of L059 (Levetiracetam) in Epilepsy Patients With Partial Onset Seizures

Information source: UCB
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Epilepsies, Partial

Intervention: Levetiracetam (Drug)

Phase: Phase 3

Status: Active, not recruiting

Sponsored by: UCB

Official(s) and/or principal investigator(s):
UCB Clinical Trial Call Center, Study Director, Affiliation: +1 877 822 9493

Summary

This study is planned to evaluate the safety and efficacy of L059 (levetiracetam) in long-term administration in patients who completed a previous study.

Clinical Details

Official title: A Multicenter, Open, Long-Term Follow-up Study to Evaluate the Safety and Efficacy of L059 (Levetiracetam) at Individual Optimal Dose Ranging From 500 to 3000 mg/Day in b.i.d. Administration in Subjects With Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized Who Completed a Previous Trial.

Study design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study

Primary outcome: The long-term safety of L059 at the dose range from 500 to 3000 mg/day in subjects who participated in the preceding studies N01020 and N01021.

Secondary outcome:

Percent reduction from baseline in the preceding study in Partial Seizure.

Seizures Frequency per Week in Partial Seizures over the first period.

Responder rate

Percent reduction from baseline according to Type of Partial Epileptic Seizures.

Eligibility

Minimum age: N/A. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients who participated in the preceding Levetiracetam studies (N01221 and N01020),

and completed the evaluation and transition period

Exclusion Criteria:

- Female patients during pregnancy, delivery and lactation or suspected of pregnancy.

Locations and Contacts

Aomori, Japan

Chiba, Japan

Fukuoka, Japan

Fukushima, Japan

Gifu, Japan

Hiroshima, Japan

Kagoshima, Japan

Kumamoto, Japan

Kyoto, Japan

Miyazaki, Japan

Niigata, Japan

Okayama, Japan

Osaka, Japan

Shizuoka, Japan

Tokyo, Japan

Toyama, Japan

Yamagata, Japan

Nagoya, Aichi, Japan

Aichi-gun, Aichi, Japan

Hirosaki, Aomori, Japan

Matsudo, Chiba, Japan

Kitakyusyu, Fukuoka, Japan

Kurume, Fukuoka, Japan

Koga, Fukuoka, Japan

Fukuyama, Hiroshima, Japan

Sapporo, Hokkaido, Japan

Asahikawa, Hokkaido, Japan

Hakodate, Hokkaido, Japan

Kobe, Hyogo, Japan

Kahoku-gun, Ishikawa, Japan

Kanazawa, Ishikawa, Japan

Zentsuji, Kagawa, Japan

Koshi, Kumamoto, Japan

Ukyo-ku, Kyoto, Japan

Tsu, Mie, Japan

Sendai, Miyagi, Japan

Iwanuma, Miyagi, Japan

Omura, Nagasaki, Japan

Kashihara, Nara, Japan

Nagaoka, Niigata, Japan

Beppu, Oita, Japan

Suita, Osaka, Japan

Takatsuki, Osaka, Japan

Izumi, Osaka, Japan

Neyagawa, Osaka, Japan

Iruma-gun, Saitama, Japan

Shimotsuga-gun, Tochigi, Japan

Kawachi-gun, Tochigi, Japan

Shimotsuke, Tochigi, Japan

Komatsujima, Tokushima, Japan

Kodaira, Tokyo, Japan

Chiyoda-Ku, Tokyo, Japan

Ube, Yamaguchi, Japan

Additional Information

Starting date: July 2006
Ending date: August 2009
Last updated: June 4, 2008

Page last updated: June 20, 2008

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012